Multiple myeloma (MM) is the second most frequently diagnosed hematological malignancy, and despite all the therapeutic advances it remains incurable due to the development of drug resistance. Recently, RNA editing has emerged as one of the important mechanisms that determines expression variability and therefore may be involved in the development of resistance to standard therapy. This process is mediated by adenosine deaminase acting on RNA (ADAR) enzymes that convert adenosines to inosines (A-->I editing) in double-stranded RNA (dsRNA) substrates. We hypothesize that ADAR1 activation in MM cells may be promoted by the normal cells of the bone marrow (BM) niche through the release of pro-tumor factor controlled by the oncogenic Notch pathway. Indeed, Notch is known to be hyperactivated in myeloma and it is crucial for the pathologic crosstalk between tumor cells and the surrounding BM microenvironment. Aim of this work was to investigate how the Notch pathway contributes to the ability of the BM microenvironment stromal cells on their ability to boost RNA editing and drug resistance in MM, in order to provide the rationale for a Notch-directed therapy that may allow to inhibit the progression of this disease.

The Notch pathway drives the ability of the bone marrow niche to promote RNA editing in multiple myeloma / M. Colombo, C. Raffaella, M. Barbieri, B. Francesco, E. Lazzari, K. Todoerti, C. Leslie, J.C. H. M., A. Neri, R. Chiaramonte. ((Intervento presentato al convegno Congresso DISS tenutosi a Milano nel 2017.

The Notch pathway drives the ability of the bone marrow niche to promote RNA editing in multiple myeloma

M. Colombo
;
M. Barbieri;E. Lazzari;K. Todoerti;A. Neri;R. Chiaramonte
Ultimo
2017-11-13

Abstract

Multiple myeloma (MM) is the second most frequently diagnosed hematological malignancy, and despite all the therapeutic advances it remains incurable due to the development of drug resistance. Recently, RNA editing has emerged as one of the important mechanisms that determines expression variability and therefore may be involved in the development of resistance to standard therapy. This process is mediated by adenosine deaminase acting on RNA (ADAR) enzymes that convert adenosines to inosines (A-->I editing) in double-stranded RNA (dsRNA) substrates. We hypothesize that ADAR1 activation in MM cells may be promoted by the normal cells of the bone marrow (BM) niche through the release of pro-tumor factor controlled by the oncogenic Notch pathway. Indeed, Notch is known to be hyperactivated in myeloma and it is crucial for the pathologic crosstalk between tumor cells and the surrounding BM microenvironment. Aim of this work was to investigate how the Notch pathway contributes to the ability of the BM microenvironment stromal cells on their ability to boost RNA editing and drug resistance in MM, in order to provide the rationale for a Notch-directed therapy that may allow to inhibit the progression of this disease.
Settore MED/04 - Patologia Generale
Settore BIO/13 - Biologia Applicata
Settore BIO/11 - Biologia Molecolare
The Notch pathway drives the ability of the bone marrow niche to promote RNA editing in multiple myeloma / M. Colombo, C. Raffaella, M. Barbieri, B. Francesco, E. Lazzari, K. Todoerti, C. Leslie, J.C. H. M., A. Neri, R. Chiaramonte. ((Intervento presentato al convegno Congresso DISS tenutosi a Milano nel 2017.
Conference Object
File in questo prodotto:
File Dimensione Formato  
Diss_ADAR1 NP.pdf

embargo fino al 02/05/2020

Tipologia: Pre-print (manoscritto inviato all'editore)
Dimensione 103.99 kB
Formato Adobe PDF
103.99 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/529193
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact